Humanized antibodies against TL1A

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9416185
APP PUB NO 20140315250A1
SERIAL NO

14244603

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TEVA BIOPHARMACEUTICALS USA INCMARYLAND USA MARYLAND

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cooksey, Bridget A Macquarie Park, AU 9 105
Kanakaraj, Palanisamy Germantown, US 8 140
Roschke, Viktor Bethesda, US 38 792
Rosen, Craig Pasadena, US 22 257
Smith, Rodger Jefferson, US 17 285

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 16, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00